Key result
Higher 79-variant genetic risk score linked to ~33% greater MACE risk per SD in ACS.
Why the study?
Evidence regarding the effects of genetic risk scores on secondary prevention of coronary artery disease is scarce and mixed.
Does a genetic risk score predict the risk of major adverse cardiovascular events in patients with acute coronary syndromes?
Cohort (n=1,667)
Does a genetic risk score predict the risk of major adverse cardiovascular events in patients with acute coronary syndromes?
A genetic risk score comprising 79 CAD risk variants independently predicts recurrent MACE in Chinese patients with ACS and slightly improves risk stratification over traditional models.
Evidence of the effects of genetic risk score (GRS) on secondary prevention is scarce and mixed. We investigated whether coronary artery disease (CAD) susceptible loci can be used to predict the risk of major adverse cardiovascular events (MACEs) in a cohort with acute coronary syndromes (ACSs). A total of 1667 patients hospitalized with ACS were enrolled and prospectively followed for a median of 2 years. We constructed a weighted GRS comprising 79 CAD risk variants and investigated the association between GRS and MACE using a multivariable cox proportional hazard regression model. The incremental value of adding GRS into the prediction model was assessed by integrated discrimination improvement (IDI) and decision curve analysis (DCA). In the age- and sex-adjusted model, each increase in standard deviation in the GRS was associated with a 33% increased risk of MACE (hazard ratio: 1.33; 95% confidence interval: 1.10-1.61; P = 0.003), with this association not attenuating after further adjustment for traditional cardiovascular risk factors. The addition of GRS to a prediction model of seven clinical risk factors and EPICOR prognostic model slightly improved risk stratification for MACE as calculated by IDI (+1.7%, P = 0.006; +0.3%, P = 0.024, respectively). DCA demonstrated positive net benefits by adding GRS to other models. GRS was associated with MACE after multivariable adjustment in a cohort comprising Chinese ACS patients. Future studies are needed to validate our results and further evaluate the predictive value of GRS in secondary prevention.
No takes yet. Share an insight, caveat, or question.
Jiang et al. (2020) conducted a cohort in Acute coronary syndromes (ACS) (n=1,667). Genetic risk score (GRS) was evaluated on Major adverse cardiovascular events (MACEs) (HR 1.33, 95% CI 1.10-1.61, p=0.003). Each standard deviation increase in a 79-variant genetic risk score was associated with a 33% increased risk of MACE in patients with acute coronary syndromes (HR 1.33; 95% CI 1.10-1.61; P=0.003).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: